CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Nucleix developed a platform for creating methylation biomarkers for early disease detection, particularly cancer. Their urine test, Bladder EpiCheck, aims to improve monitoring of bladder cancer patients using specific DNA methylation markers.
Nucleix developed a revolutionary platform for the development of Methylation Bio-markers and Bio-Marker panels for screening (early detection of disease) and diagnosis based on epigenetic markers.
The platform identifies changes in specific methylation locations of DNA extracted from body fluids such as – urine, blood, stools and sputum. A Bio-Markers panel goal is to distinguish between sick and healthy individuals.
The company’s expertise include the identification of the specific loci, co…
NUCLEIX LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
